News | Radiopharmaceuticals and Tracers | July 01, 2019

Bracco Imaging Acquires Blue Earth Diagnostics

Transaction set to close in Q3 2019, bringing Axumin novel PET imaging agent into Bracco product portfolio

Bracco Imaging Acquires Blue Earth Diagnostics

July 1, 2019 — Bracco Imaging S.p.A. has signed a definitive agreement to acquire Blue Earth Diagnostics, a molecular imaging company based in Oxford, U.K. Subject to customary closing conditions, completion of the transaction is expected in the third quarter of this calendar year.

Bracco Imaging will acquire all outstanding shares of privately-held Blue Earth Diagnostics for the equity value of $450 million, plus closing adjustment estimated at $25 million, from healthcare company Syncona and Blue Earth Diagnostics' management team. Upon closing of the transaction, Blue Earth Diagnostics will be a subsidiary of Bracco Imaging, led by its current leadership team and will retain the Blue Earth Diagnostics name. Blue Earth Diagnostics employs approximately 100 people and is expected to generate revenues of $140 million in the year to September 2019, primarily in the U.S.

The first novel positron emission tomography (PET) molecular imaging agent developed by Blue Earth Diagnostics is Axumin (F18-fluciclovine) injection. Axumin is approved in the U.S. and the European Union for PET imaging in men with suspected recurrent prostate cancer based on elevated prostate specific antigen (PSA) levels following prior treatment. The company's pipeline includes prostate specific membrane antigen (PSMA)-targeted radiohybrid ("rh") agents, which are a clinical-stage, investigational class of theranostic compounds, with potential applications in both the imaging and treatment of prostate cancer.

Prostate cancer is the most common cancer in men, with an estimated number of more than 170 thousand new cases in 2019 in the U.S. While most cases of primary prostate cancer can be treated successfully, the cancer will recur in up to one third of cases and in a third of those recurrences, patients develop distant metastases leading to a fatal outcome. In two separate studies which evaluated the utility of Axumin (F18-fluciclovine) PET/CT (computed tomography) in providing physicians with actionable information for the management of men with recurrent prostate cancer, the intended management plan was changed for approximately 60 percent of the study subjects, based on the results of the Axumin PET/CT scan.

F18-fluciclovine has a broad range of other potential applications in cancer imaging and Blue Earth Diagnostics is investigating the molecule for other cancers including in neuro-oncology.

For more information: www.braccoimaging.com, www.blueearthdiagnostics.com

Related Content

A 3-D ultrasound system provides an effective, noninvasive way to estimate blood flow that retains its accuracy across different equipment, operators and facilities, according to a study published in the journal Radiology.

Volume flow as a function of color flow gain (at a single testing site). For each row the color flow c-plane and the computed volume flow are shown as a function of color flow gain. The c-plane is shown for four representative gain levels, whereas the computed volume flow is shown for 12–17 steps across the available gain settings. Flow was computed with (solid circles on the graphs) and without (hollow circles on the graphs) partial volume correction. Partial volume correction accounts for pixels that are only partially inside the lumen. Therefore, high gain (ie, blooming) does not result in overestimation of flow. Systems 1 and 2 converge to true flow after the lumen is filled with color pixel. System 3 is nearly constant regarding gain and underestimates the flow by approximately 17%. Shown are mean flow estimated from 20 volumes, and the error bars show standard deviation. Image courtesy of the journal Radiology

News | Ultrasound Imaging | July 01, 2020
July 1, 2020 — A 3-D ultrasound
Researchers reviewed results of prostate biopsies on over 3,400 men who had targets identified on prostate MRI and found that the positive predictive value of the test for prostate cancer was highly variable at different sites
News | Prostate Cancer | July 01, 2020
July 1, 2020 — Prostate MRI is an emerging technology used to identify and guide treatment for...
R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

R2* maps of healthy control participants and participants with Alzheimer disease. R2* maps are windowed between 10 and 50 sec21. Differences in iron concentration in basal ganglia are too small to allow visual separation between patients with Alzheimer disease and control participants, and iron levels strongly depend on anatomic structure and subject age. Image courtesy of Radiological Society of North America

News | Magnetic Resonance Imaging (MRI) | July 01, 2020
July 1, 2020 — Researchers using magnetic...
Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosai

Thoracic findings in a 15-year-old girl with Multisystem Inflammatory Syndrome in Children (MIS-C). (a) Chest radiograph on admission shows mild perihilar bronchial wall cuffing. (b) Chest radiograph on the third day of admission demonstrates extensive airspace opacification with a mid and lower zone predominance. (c, d) Contrast-enhanced axial CT chest of the thorax at day 3 shows areas of ground-glass opacification (GGO) and dense airspace consolidation with air bronchograms. (c) This conformed to a mosaic pattern with a bronchocentric distribution to the GGO (white arrow, d) involving both central and peripheral lung parenchyma with pleural effusions (black small arrow, d). image courtesy of Radiological Society of North America

News | Coronavirus (COVID-19) | June 26, 2020
June 26, 2020 — In recent weeks, a multisystem hyperinflammatory condition has emerged in children in association wit
n support of Mayo Clinic’s digital health and practice transformation initiatives, the Mayo Clinic Department of Laboratory Medicine and Pathology has initiated an enterprise-wide digital pathology implementation of the Sectra digital slide review and image storage and management system to enable digital pathology. 
News | Enterprise Imaging | June 26, 2020
June 26, 2020 —  In support of Mayo Clinic’s digital health
Two leading organizations join forces to drive future telehealth strategies across hospital settings into the home propelled by COVID-19
News | Teleradiology | June 18, 2020
June 18, 2020 — Philips announced it has once again joined forces with the American Telemedicine Association (...
Axial FLAIR in four different COVID-19 patients. A) 58-year old man with impaired consciousness: FLAIR hyperintensities located in the left medial temporal lobe. B) 66-year old man with impaired consciousness: FLAIR ovoid hyperintense lesion located in the central part of the splenium of the corpus callosum. C) 71-year old woman with pathological wakefulness after sedation: extensive and confluent supratentorial white matter FLAIR hyperintensities (arrows). Association with leptomeningeal enhancement (stars

Axial FLAIR in four different COVID-19 patients. A) 58-year old man with impaired consciousness: FLAIR hyperintensities located in the left medial temporal lobe. B) 66-year old man with impaired consciousness: FLAIR ovoid hyperintense lesion located in the central part of the splenium of the corpus callosum. C) 71-year old woman with pathological wakefulness after sedation: extensive and confluent supratentorial white matter FLAIR hyperintensities (arrows). Association with leptomeningeal enhancement (stars) D) 61-year old man with confusion: hyperintense lesions involving both middle cerebellar peduncles. Image courtesy of the journal Radiology

News | Coronavirus (COVID-19) | June 16, 2020
June 16, 2020 — Current data on central nervous system (CNS) involvement in...
New software version for Vantage Orian 1.5T also offers cybersecurity solutions to protect patient data
News | Magnetic Resonance Imaging (MRI) | June 15, 2020
June 15, 2020 — Hospitals and institutions are continually looking for ways to improve diagnostic imaging throughput,